Asthma Clinical Trial
— INHALEOfficial title:
Individualized Nutrition to Help Asthmatics Improve Lung Function and Energetics (INHALE)
Determine to what extent three distinct dietary approaches improve asthma control and lung function.
| Status | Recruiting |
| Enrollment | 15 |
| Est. completion date | March 1, 2027 |
| Est. primary completion date | December 31, 2026 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 18 Years to 65 Years |
| Eligibility | Inclusion Criteria: - Age: 18-65 years - BMI: 18.5 - 29.99 kg/m2 - asthma diagnosed by medical specialist (confirmed in medical history) - partly controlled or uncontrolled asthma by Asthma Control Test score =22 - owns a device compatible with ZEPHYRx platform - stable asthma medication use (no change in the past 2 months). Exclusion Criteria: - Diabetes or using diabetes medications that may lower blood glucose levels - point of care fasting blood glucose =126 mg/dl or triglycerides =400 mg/dl - current smoking or smoking history of greater than 10 pack-years - other significant respiratory or cardiac disease or the presence of clinically important comorbidities, e.g., COPD, renal failure, liver disease; uncontrolled hypertension defined as systolic blood pressure =160 mm/Hg, or diastolic blood pressure =100 mm/Hg - pregnant or nursing women - food preferences or allergies inconsistent with study diet capabilities - noncompliance with lead-in period requirements. |
| Country | Name | City | State |
|---|---|---|---|
| United States | Pennington Biomedical Research Center | Baton Rouge | Louisiana |
| Lead Sponsor | Collaborator |
|---|---|
| Pennington Biomedical Research Center | National Heart, Lung, and Blood Institute (NHLBI) |
United States,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Other | indirect calorimetry | nutrient utilization according to respiratory exchange ratio (0.66 - 1.0) | baseline, after 7 days on Diet#1, after 7 days on Diet#2, after 7 days on Diet#3 | |
| Other | ketosis | plasma ß-hydroxybutyrate (mM) | baseline, after 7 days on Diet#1, after 7 days on Diet#2, after 7 days on Diet#3 | |
| Other | eosinophilic asthma characterization | absolute blood eosinophils (count) | baseline, after 7 days on Diet#1, after 7 days on Diet#2, after 7 days on Diet#3 | |
| Other | immunoglobulin asthma characterization | blood immunoglobulin E (IgE) | baseline, after 7 days on Diet#1, after 7 days on Diet#2, after 7 days on Diet#3 | |
| Other | systemic inflammation | blood cytokines (IL17, TNFa, IL1ß) | baseline, after 7 days on Diet#1, after 7 days on Diet#2, after 7 days on Diet#3 | |
| Primary | Asthma Control | Asthma Control Questionnaire score (Juniper; 1 week recall period) Score range: 0-6. Minimally important difference = 0.5. | Baseline | |
| Primary | Asthma Control | Asthma Control Questionnaire score (Juniper; 1 week recall period) Score range: 0-6. Minimally important difference = 0.5. | After 7 days on Diet#1 | |
| Primary | Asthma Control | Asthma Control Questionnaire score (Juniper; 1 week recall period) Score range: 0-6. Minimally important difference = 0.5. | After 7 days on Diet#2 | |
| Primary | Asthma Control | Asthma Control Questionnaire score (Juniper; 1 week recall period) Score range: 0-6. Minimally important difference = 0.5. | After 7 days on Diet#3 | |
| Primary | Lung Function | FEV1 (forced expiratory volume in 1 second; % of predicted) | Baseline | |
| Primary | Lung Function | FEV1 (forced expiratory volume in 1 second; % of predicted) | After 7 days on Diet#1 | |
| Primary | Lung Function | FEV1 (forced expiratory volume in 1 second; % of predicted) | After 7 days on Diet#2 | |
| Primary | Lung Function | FEV1 (forced expiratory volume in 1 second; % of predicted) | After 7 days on Diet#3 | |
| Secondary | Systemic inflammation | plasma interleukin-6 (IL6) | Baseline | |
| Secondary | Systemic inflammation | plasma interleukin-6 (IL6) | After 7 days on Diet#1 | |
| Secondary | Systemic inflammation | plasma interleukin-6 (IL6) | After 7 days on Diet#2 | |
| Secondary | Systemic inflammation | plasma interleukin-6 (IL6) | After 7 days on Diet#3 | |
| Secondary | FENO | FENO (ppm) | Baseline | |
| Secondary | FENO | FENO (ppm) | After 7 days on Diet#1 | |
| Secondary | FENO | FENO (ppm) | After 7 days on Diet#2 | |
| Secondary | FENO | FENO (ppm) | After 7 days on Diet#3 | |
| Secondary | FEV1/FVC | FEV1/Forced Vital Capacity (FVC) ratio | Baseline | |
| Secondary | FEV1/FVC | FEV1/Forced Vital Capacity (FVC) ratio | After 7 days on Diet#1 | |
| Secondary | FEV1/FVC | FEV1/Forced Vital Capacity (FVC) ratio | After 7 days on Diet#2 | |
| Secondary | FEV1/FVC | FEV1/Forced Vital Capacity (FVC) ratio | After 7 days on Diet#3 |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
| Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
| Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
| Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
| Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
| Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
| Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
| Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
| Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
| Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
| Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
| Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
| Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
| Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
| Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
| Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
| Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
| Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
| Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|